Background: Neurofilament light chain (NFL) in blood has been identified as a valuable biomarker in multiple system atrophy (MSA), but data regarding its utility in the early diagnosis and prognosis of MSA remain limited.
Objective: To investigate serum NFL's diagnostic and prognostic value in patients with MSA in a prospective clinical cohort.
Methods: Two hundred twenty-eight participants were enrolled, including ninety-eight with MSA, seventeen with uncertain MSA at inclusion, fifty-nine with Parkinson's disease (PD), and fifty-four healthy controls (HCs). Patients with MSA and uncertain diagnoses were followed up. Serum NFL levels were measured with electrochemiluminescence immunoassay at baseline.
Results: Patients with MSA and uncertain diagnoses underwent repeated clinical assessments with a median follow-up period of 1.43 years. The final diagnoses included 102 MSA, 62 PD, and 54 HCs. Serum NFL levels were significantly higher in MSA and PD than in HCs. Serum NFL levels, with cutoff values of 223.5 and 218.0 pg/mL, could discriminate between patients with MSA and PD (AUC = 0.930) in the early disease stages, and between MSA-parkinsonism subtypes and PD (AUC = 0.878). Higher serum NFL levels were independently associated with a shorter median time to poor prognosis and death. In addition, reduced levodopa responsiveness was correlated with poor outcomes, and orthostatic hypotension (OH) was linked to a higher risk of death.
Conclusion: Serum NFL levels can not only differentiate between MSA, MSA-P, and PD in the early stages of the disease but also serve as a reliable independent predictor of poor prognosis and survival time in MSA.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00415-024-12784-5 | DOI Listing |
Front Aging Neurosci
December 2024
Department of Neurology, Tianjin Huanhu Hospital, Tianjin, China.
Background: Neurofilament light chain (NfL) has recently emerged as a key indicator of neurodegeneration. In this study, our hypothesis is that the levels of blood-derived NfL and its accumulation during the Parkinson's disease (PD) progression could serve as a potential biomarker for predicting subsequent cognitive decline. To investigate this, we conducted a study utilizing a large single-center cohort.
View Article and Find Full Text PDFJ Neurol
December 2024
Department of Neurology, Neurobiology and Geriatrics, Xuanwu Hospital Capital Medical University, Beijing Institute of Geriatrics, 45 Changchun Street, Xicheng District, Beijing, 100053, China.
Background: Neurofilament light chain (NFL) in blood has been identified as a valuable biomarker in multiple system atrophy (MSA), but data regarding its utility in the early diagnosis and prognosis of MSA remain limited.
Objective: To investigate serum NFL's diagnostic and prognostic value in patients with MSA in a prospective clinical cohort.
Methods: Two hundred twenty-eight participants were enrolled, including ninety-eight with MSA, seventeen with uncertain MSA at inclusion, fifty-nine with Parkinson's disease (PD), and fifty-four healthy controls (HCs).
BMJ Neurol Open
December 2024
Department of Medical Physics, Isfahan University of Medical Sciences, Isfahan, Iran (the Islamic Republic of).
Background: Multiple sclerosis (MS) is a chronic neuroinflammatory condition characterised by demyelination and axonal damage in the central nervous system. Diffusion tensor imaging (DTI) enables non-invasive investigation of microstructural white matter alterations, while serum neurofilament light chain (NFL) holds promise as a fluid biomarker of axonal injury.
Objectives: To use DTI and serum NFL measurements to evaluate white matter pathology in patients with MS and explore the relationship between in vivo imaging and biochemical indicators of axonal damage.
Inflammation
December 2024
Department of Neurology, CRC Sclérose en Plaques, CHU Montpellier, Univ Montpellier, INSERM, Montpellier, France.
Multiple sclerosis (MS) is a complex, chronic inflammatory disease of the central nervous system, where immune dysregulation plays a critical role. We sought to explore the modulation of the pro-inflammatory cytokines tumor necrosis factor-alpha (TNFɑ) and TNF-like weak inducer of apoptosis (TWEAK), along with their respective autoantibodies, TNAb and TWAb, and to decipher potential associations between these and clinical characteristics which could assist personalized therapy in MS. We also assessed the complementarity to leading candidate biomarkers in MS patient monitoring, namely, glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL).
View Article and Find Full Text PDFJ Affect Disord
December 2024
Department of School of Public Health and Emergency Medicine, Southern University of Science and Technology, No. 1088 Xueyuan Avenue, Shenzhen 518055, China. Electronic address:
Introduction: Neurofilament light chain (NfL) is a specific biomarker of neuroaxonal damage and related neurodegenerative diseases. Aging acceleration, which reflects the impact of modifiable factors on the aging process, is increasingly recognized for its relevance. While normal aging is known to contribute substantially to neuroaxonal damage and many neurodegenerative diseases, the effects of aging acceleration warrant further investigation.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!